drugset / Trial / NCT00203372
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.
Timeline
- Start
- 2005-05
- Primary completion
- 2012-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |